NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms

Area of Science:

• Molecular Biology
• Oncology
• Immunology

Background:

• The Nuclear Factor kappa B (NF-κB) pathway is a critical regulator of apoptosis and cellular functions.
• Constitutive activation of the NF-κB pathway contributes to cancer development, progression, and therapy resistance.
• The NF-κB pathway's role in normal and cancer cells makes it a significant therapeutic target.

Purpose of the Study:

• To review the physiological role of the NF-κB pathway.
• To discuss recent advances in understanding the pathological roles of the NF-κB pathway in lymphoid neoplasms.
• To update on clinical trials investigating NF-κB pathway inhibitors.

Main Methods:

• Literature review of physiological and pathological roles of NF-κB.
• Analysis of current clinical trials involving NF-κB pathway inhibitors.
• Synthesis of information on therapeutic strategies targeting NF-κB.

Main Results:

• The NF-κB pathway's activation promotes cancer by enhancing anti-apoptotic mechanisms, altering the microenvironment, and causing gene dysregulation.
• NF-κB pathway inhibitors are under investigation in clinical trials for lymphoid neoplasms.
• Combination therapies involving NF-κB inhibitors aim to optimize cancer eradication.

Conclusions:

• Targeting the NF-κB pathway offers promising therapeutic opportunities for lymphoid neoplasms.
• Understanding the dual role of NF-κB in normal and malignant cells is key for effective therapy.
• Clinical trials are actively exploring novel strategies combining NF-κB inhibitors with other agents.